DO-BO

Dynamic Rebates, Drug Tenders & AMNOG: Is Germany Rewriting the Rules for Pharma, Thomas Hammerschmidt?

What happens to pharma in Germany when the rules of AMNOG change? In this MAP episode, Dr. Stefan Walzer talks with Prof. Dr. Thomas Hammerschmidt, expert in pharmaceutical management at the Technical University of Applied Sciences Rosenheim (TH Rosenheim), about the latest proposals affecting AMNOG, drug pricing, reimbursement, and market access in Germany.

They discuss dynamic mandatory rebates, tenders for patented drugs, and price-volume agreements, and what these could mean for pharmaceutical companies. Thomas also explains why removing combination rebates and AMNOG guardrails could strengthen incentives for innovation. His key message: companies should prepare for stronger pricing pressure, more uncertainty, and a changing reimbursement landscape, while Germany faces the question of how to contain costs and still reward innovation.

Related

Is the EU Joint Clinical Assessment just another administrative layer, or the start of a truly European HTA? In this MAP episode, Dr. Stefan Walzer talks with Dr. Oriol Solà-Morales, physician, health economist, founder and CEO of HITT and founding member of EUnetHTA, about what the first JCA reports reveal. Drawing on Spain’s shift from […]

AI is reshaping health economics and outcomes research (HEOR) – but where does it truly belong? In this MAP episode, Dr. Stefan Walzer talks with Haidong Feng, Associate Principal Scientist at Merck, about “human in the loop” versus “AI in the loop” and why the two complement rather than contradict each other. Haidong explains why […]

When the US benchmarks drug prices against other countries, the whole world feels it. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Brittany La Couture of Applied Policy, a health policy attorney with eight years at the Centers for Medicare & Medicaid Services, to unpack the US […]